Effects of homoeopathic medicine Tinospora cordifolia on treatment of Hyperuricemia in compared with placebo

Efficacy of homoeopathic medicine Tinospora Cordifolia in its centesimal potencies for hyperuricemia among 20-70 years aged: A single blind, randomized, placebo controlled trial. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/075139

Enrollment

Registered

2024-10-11

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E790- Hyperuricemia without signs of inflammatory arthritis and tophaceous disease

Interventions

Intervention1: Homoeopathic medicine Tinospora cordifolia: Intervention is planned as administering homoeopathic medicine Tinospora cordifolia in centesimal potencies, as decided appropriate to the ca

14 doses are to be marked on the phial. All medicines will be procured from a Good Manufacturing Practice-certified firm. Along with medicines, the intervention arm will receive advice on general mana

14 doses are to be marked on the phial. All items will be procured from a Good Manufacturing Practice-certified firm. Duration of therapy: 6 months.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Persons diagnosed with hyperuricemia at laboratory report (2020 ICD-10-CM Diagnosis Code E.79.0). 2. Serum uric acid level above 7.0mg/dl to 10.0mg/dl in males and above 6.0mg/dl to 10.0mg/dl in females. 3. 20 to 70 years aged both male and female who are not taking any other regular medication for a chronic condition. 4. Both sexes. 5. Participants is able to read and understand the provided information and has given written consent to participate.

Exclusion criteria

Exclusion criteria: 1. Patients with cases of overt hyperuricemia (uric acid level more than 10 mg/dl). 2. Patient having secondary gout. 3. Patient with severe or advanced stage of gout and/or joint deformity that require surgical procedures or orthopedic corrections. 4. Patients having major metabolic disorders, enzymatic disorders and uncontrolled systemic illness and/or infections including cancer. 5. Patients with unstable mental or psychiatric illness. 6. Pregnant women, puerperal women and lactating women. 7. Drug addict and alcohol-consuming patients. 8. Self reported Immuno-compromised patients.

Design outcomes

Primary

Measure	Time frame
Changes in Serum Uric Acid LevelTimepoint: 6 months	—

Secondary

Measure	Time frame
Score of Gout Impact Scale- impact of Hyperuricemia on Quality of Life Questionnaire (GIS-HRQoL)Timepoint: 6 months	—

Countries

India

Contacts

Public ContactChandrani Ghosh

METROPOLITAN HOMOEOPATHIC MEDICAL COLLEGE AND HOSPITAL

dr.cndas@rediffmail.com9874432608

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026